Viracept nelfinavir HIV protease inhibitor data

Researchers presented 12-month data at the Interscience Conference on Antimicrobial Agents and Chemotherapy in Toronto from a trial of AGPH's Viracept in combination with Glaxo Wellcome's AZT and BioChem Pharma Inc.'s Epivir 3TC. The trial assessed 297 patients with a mean viral load of 153,044 viral copies/mL and a mean CD4 count of 288.

Viral load fell below

Read the full 587 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE